Abstract
Thai patients enrolled in STACCATO with HIV/hepatitis B virus (HBV) co-infection and tenofovir/emtricitabine-based antiretroviral therapy (ART) were randomly assigned to continuous treatment or CD4 cell count-guided interruptions. HBV replication was suppressed below detection in 15/16 patients. Structured treatment interruption increased transaminases and HBV viraemia in five of six patients; one flare was severe. Conversion to anti-hepatitis Be occurred with continuous treatment only. Tenofovir/emtricitabine-containing ART is highly effective in controlling chronic HIV/HBV co-infection but treatment should not be interrupted.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adenine / administration & dosage
-
Adenine / analogs & derivatives*
-
Anti-Retroviral Agents / administration & dosage
-
Antiretroviral Therapy, Highly Active
-
Antiviral Agents / administration & dosage*
-
Deoxycytidine / administration & dosage
-
Deoxycytidine / analogs & derivatives*
-
Drug Administration Schedule
-
Emtricitabine
-
Female
-
HIV Infections / complications*
-
HIV Infections / drug therapy*
-
HIV*
-
Hepatitis B e Antigens / blood
-
Hepatitis B virus* / immunology
-
Hepatitis B virus* / isolation & purification
-
Hepatitis B, Chronic / blood
-
Hepatitis B, Chronic / complications*
-
Hepatitis B, Chronic / drug therapy*
-
Hepatitis B, Chronic / virology
-
Humans
-
Male
-
Organophosphonates / administration & dosage*
-
Tenofovir
-
Thailand
-
Transaminases / blood
-
Treatment Outcome
-
Viral Load
Substances
-
Anti-Retroviral Agents
-
Antiviral Agents
-
Hepatitis B e Antigens
-
Organophosphonates
-
Deoxycytidine
-
Tenofovir
-
Transaminases
-
Emtricitabine
-
Adenine